The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지

Synergistic Efficacy of Concurrent Treatment with Cilostazol and Probucol on the Suppression of Reactive Oxygen Species and Inflammatory Markers in Cultured Human Coronary Artery Endothelial Cells

  • Park, So-Youn (Departments of Pharmacology, Pusan National University College of Medicine) ;
  • Lee, Jeong-Hyun (Departments of Pharmacology, Pusan National University College of Medicine) ;
  • Shin, Hwa-Kyoung (Medical Research Center for Ischemic Tissue Regeneration, Pusan National University College of Medicine) ;
  • Kim, Chi-Dae (Departments of Pharmacology, Medical Research Center for Ischemic Tissue Regeneration, Pusan National University College of Medicine) ;
  • Lee, Won-Suk (Departments of Pharmacology, Medical Research Center for Ischemic Tissue Regeneration, Pusan National University College of Medicine) ;
  • Rhim, Byung-Yong (Departments of Pharmacology, Pusan National University College of Medicine) ;
  • Shin, Yung-Woo (Departments of Internal Medicine, Pusan National University College of Medicine) ;
  • Hong, Ki-Whan (Medical Research Center for Ischemic Tissue Regeneration, Pusan National University College of Medicine)
  • Published : 2008.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

In the present study, we aimed to identify the synergistic effects of concurrent treatment of low concentrations of cilostazol and probucol to inhibit the oxidative stress with suppression of inflammatory markers in the cultured human coronary artery endothelial cells (HCAECs). Combination of cilostazol (0.3${\sim}3{\mu}$M) with probucol (0.03${\sim}0.3{\mu}$M) significantly suppressed TNF-${\alpha}$-stimulated NAD(P)H-dependent superoxide, lipopolysaccharide (LPS)-induced intracellular reactive oxygen species (ROS) production and TNF-${\alpha}$ release in comparison with probucol or cilostazol alone. The combination of cilostazol (0.3${\sim}3{\mu}$M) with probucol (0.1${\sim}0.3{\mu}$M) inhibited the expression of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1) more significantly than did the monotherapy with either probucol or cilostazol. In line with these results, combination therapy significantly suppressed monocyte adhesion to endothelial cells. Taken together, it is suggested that the synergistic effectiveness of the combination therapy with cilostazol and probucol may provide a beneficial therapeutic window in preventing atherosclerosis and protecting from cerebral ischemic injury.

Keywords

References

  1. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial- leukocyte adhesion molecules in human disease. Annu Rev Med 45: 361-378, 1994 https://doi.org/10.1146/annurev.med.45.1.361
  2. Bilenko MV, Khil'chenko AV, Konovalova GG, Lankin VZ. Effect of antioxidant probucol on cell-mediated LDL oxidation in vitro and in vivo. Bull Exp Biol Med 136: 126-128, 2003 https://doi.org/10.1023/A:1026398319379
  3. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 84: 7725-7772, 1987
  4. Choi JM, Shin HK, Kim KY, Lee JH, Hong KW. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300: 787-793, 2002 https://doi.org/10.1124/jpet.300.3.787
  5. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos J-C, Connelly PW, Milstone DS. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107: 1255-1262, 2001 https://doi.org/10.1172/JCI11871
  6. Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, Cybulsky MI, Smith JD. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol 21: 662-1667, 2001
  7. Faruqi R, de la Motte C, DiCorleto PE. Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest 94: 92-600, 1994
  8. Ferns GA, Forster L, Stewart-Lee A, Nourooz-Zadeh J, Anggard EE. Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit. Atherosclerosis 100: 171-181, 1993 https://doi.org/10.1016/0021-9150(93)90203-7
  9. Fruebis J, Gonzalez V, Silvestre M, Palinski W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 17: 1289-1302, 1997 https://doi.org/10.1161/01.ATV.17.7.1289
  10. Fruebis J, Silvestre M, Shelton D, Napoli C, Palinski W. Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits. J Lipid Res 40: 1958-1966, 1999
  11. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2: 275-281, 1998 https://doi.org/10.1016/S1097-2765(00)80139-2
  12. Hong KW, Kim KY, Shin HK, Lee JH, Choi JM, Kwak YG, Kim CD, Lee WS, Rhim BY. Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/cyclic AMP response element- binding protein phosphorylation. J Pharmacol Exp Ther 306: 1182-1190, 2003 https://doi.org/10.1124/jpet.103.052365
  13. Johansson J, Olsson AG, Bergstrand L, Elinder LS, Nilsson S, Erikson U, Molgoard J, Holme I, Walldius G. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler Thromb Vasc Biol 15: 1049-1056, 1995
  14. Kim KY, Shin HK, Choi JM, Hong KW. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 300: 709-715, 2002 https://doi.org/10.1124/jpet.300.2.709
  15. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35: 1144-1149, 1985
  16. Kockx MM. Apoptosis in the atherosclerotic plaque: quantitative and qualitative aspects. Arterioscler Thromb Vasc Biol 18: 1519-1522, 1998 https://doi.org/10.1161/01.ATV.18.10.1519
  17. Kuzuya M, Kuzuya F. Probucol as an antioxidant and antiatherogenic drug. Free Radic Biol Med 14: 67-77, 1993 https://doi.org/10.1016/0891-5849(93)90510-2
  18. Li PF, Dietz R, von Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation 96: 3602-3609, 1997 https://doi.org/10.1161/01.CIR.96.10.3602
  19. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91: 2844-2850, 1995 https://doi.org/10.1161/01.CIR.91.11.2844
  20. Mallikaarjun S, Forbes WP, Bramer SL. Interaction potential and tolerability of the coadministration of cilostazol and aspirin. Clin Pharmacokinet 37 Suppl 2: 87-93, 1999
  21. Park SY, Lee JH, Kim CD, Lee WS, Park WS, Han J, Kwak Y-G, Kim KY, Hong KW. Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation. J Pharmacol Exp Ther 317: 1238-1245, 2006 https://doi.org/10.1124/jpet.105.098509
  22. Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, Hong KW. Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats. Brain Res 1157: 112-120, 2007 https://doi.org/10.1016/j.brainres.2007.04.051
  23. Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, Hong KW. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther 312: 1241-1248, 2005
  24. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 147: 213-225, 1999 https://doi.org/10.1016/S0021-9150(99)00346-9
  25. Reinoehl J, Frankovich D, Machado C, Kawasaki R, Baga JJ, Pires LA, Steinman RT, Fromm BS, Lehmann MH. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 131: 1184-1191, 1996 https://doi.org/10.1016/S0002-8703(96)90095-2
  26. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993 https://doi.org/10.1038/362801a0
  27. Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 82: 144-147, 1998 https://doi.org/10.1016/S0002-9149(98)00323-3
  28. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109: 1022-1028, 2004 https://doi.org/10.1161/01.CIR.0000117403.64398.53
  29. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 337: 365-372, 1997 https://doi.org/10.1056/NEJM199708073370601
  30. Zapolska-Downar D, Zapolski-Downar A, Markiewski M, Ciechanowicz A, Kaczmarczyk M, Naruszewicz M. Selective inhibition by probucol of vascular cell adhesion molecule-1 (VCAM-1) expression in human vascular endothelial cells. Atherosclerosis 155: 123-130, 2001 https://doi.org/10.1016/S0021-9150(00)00553-0